The integration typically leads to tumor-specific truncation mutations that maintain the expression of sT and LT truncation (LTT) mutants, which conserve the N-terminal RB-binding LXCXE motif critical for inhibiting RB’s tumor suppressive role (100–104). The gene discussed is RB1; the disease is neoplasm.